Roy M Speck

US Patent:

59941405, Nov 30, 1999

Filed:

Feb 10, 1998

Appl. No.:

9/021305

Inventors:

Roy E. Speck - Indianapolis IN

Assignee:

Analytical Control Systems, Inc. - Fishers IN

International Classification:

G01N 3386

US Classification:

436 16

Abstract:

A coagulation control sample material for reproducibly monitoring coagulation control capability in a human patient wherein the coagulation control sample material has a predetermined clotting time within the range of from normal to abnormal human clotting times, the control comprising mammalian blood coagulation factors and an amount of at least one non-primate mammalian coagulation factor wherein when the coagulation control sample material has an abnormal human clotting time, the coagulation control comprises an amount of at least one non-primate plasma which has been treated with an adsorbent that adsorbs factors II, VII, IX and X and wherein the coagulation control is stable in the absence of buffer.

US Patent:

59069422, May 25, 1999

Filed:

Sep 11, 1997

Appl. No.:

8/927894

Inventors:

Roy E. Speck - Indianapolis IN

Assignee:

Analytical Control Systems, Inc. - Fishers IN

International Classification:

G01N 3386

US Classification:

436 16

Abstract:

A method for preparing a coagulation control sample which is stable in the absence of buffer and which has a clotting time within the range of normal human clotting times for reproducibly monitoring coagulation capability in a human patient comprising (a) collecting blood from a mammalian animal, (b) removing red blood cells from the blood to produce mammalian plasma, and (c) adding to the plasma an amount of at least one non-primate mammalian plasma that has been adsorbed with a coagulation factors II, VII, IX and X adsorbent prior to addition of the plasma to the mammalian plasma.

US Patent:

57211400, Feb 24, 1998

Filed:

Jun 2, 1995

Appl. No.:

8/458632

Inventors:

Roy E. Speck - Indianapolis IN

Assignee:

Analytical Control Systems, Inc. - Fishers IN

International Classification:

G01N 3386
C12Q 156

US Classification:

436 16

Abstract:

A coagulation control sample material for reproducibly monitoring coagulation control capability in a human patient wherein the coagulation control sample material has a predetermined clotting time within the range of from normal to abnormal human clotting times, the control comprising mammalian blood coagulation factors and an amount of at least one non-primate mammalian coagulation factor wherein when the coagulation control sample material has an abnormal human clotting time, the coagulation control comprises an amount of at least one non-primate plasma which has been treated with an adsorbent that adsorbs factors II, VII, IX and X and wherein the coagulation control is stable in the absence of buffer.

US Patent:

55695906, Oct 29, 1996

Filed:

Feb 16, 1995

Appl. No.:

8/390273

Inventors:

Roy E. Speck - Indianapolis IN

Assignee:

Analytical Control Systems, Inc. - Fishers IN

International Classification:

F41A 3300
G01N 3366

US Classification:

435 13

Abstract:

Described is a novel screening method for detecting an abnormal platelet condition in blood, and a kit for use in such a method. An initial screen for an abnormal platelet condition in blood applies to a non-interfering test surface a platelet rich plasma specimen from the blood and an aqueous reagent including a hydroxy-substituted aromatic compound (preferrably propyl gallate) and a metal ion, (such as Ni. sup. 2+, Co. sup. 2+, or Cu. sup. 2+) in concentrations sufficient to cause platelet aggregation in a normal platelet rich plasma sample upon agitation, lightly agitating the platelet rich plasma specimen in contact with the reagent, and visually detecting for the presence of platelet aggregates in the specimen.

US Patent:

56374526, Jun 10, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/477694

Inventors:

Roy E. Speck - Indianapolis IN

Assignee:

Analytical Control Systems, Inc. - Fishers IN

International Classification:

C12Q 100
C12Q 156
G01N 3386

US Classification:

435 4

Abstract:

Described is a novel screening method for detecting an abnormal platelet condition in blood, and a kit for use in such a method. An initial screen for an abnormal platelet condition in blood applies to a non-interfering test surface a platelet rich plasma specimen from the blood and an aqueous reagent including a hydroxy-substituted aromatic compound such as elagic acid, tannin or preferably propyl gallate and a metal ion such as Ni. sup. 2+, Co. sup. 2+, Fe. sup. 3+, Cu. sup. + or Cu. sup. 2+ in concentrations sufficient to cause platelet aggregation in a normal platelet rich plasma sample upon agitation, lightly agitating the platelet rich plasma specimen in contact with the reagent, and visually detecting for the presence of platelet aggregates in the specimen.

US Patent:

57006342, Dec 23, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/477696

Inventors:

Roy E. Speck - Indianapolis IN

Assignee:

Analytical Control Systems, Inc. - Fishers IN

International Classification:

C12Q 100
C12Q 156
G01N 3386

US Classification:

435 4

Abstract:

Novel assays and reagents for determining coagulative properties of blood or plasma are disclosed, as are agents and methods for stemming bleeding. Novel ellagic acid-based activators consist essentially of aqueous solutions of ellagic acid, phenol and suitable metal ions and give defined values for a novel platelet assay also disclosed. Inventive coagulation reagents including propyl gallate or tannin are also disclosed, as are aPTT reagents having sensitivity to heparin and Factor deficiencies far superior to prior aPTT reagents. Disclosed heparin-sensitive reagents include dextran sulfate. Also disclosed is applicant's discovery that reagents including hydroxy-substituted compounds and metal ions, heretofore known to activate Hagemann Factor, also cause platelets to release Platelet Factor 3, and a series of platelet-sensitive tests found to be enabled by this discovery. These platelet-sensitive tests include assays for platelet activity, systemic lupus, platelet reserve, which can signify type II lipoprotein defects, and for Platelet Factor 4. Disclosed methods and materials for stemming bleeding center around applicant's discovery that bleeding from bleeding sites can be stopped up to six time faster by applying to the site a hemostatic agent including effective amounts of hydroxy-substituted aromatic compound and metal ion.

US Patent:

57098891, Jan 20, 1998

Filed:

Feb 17, 1995

Appl. No.:

8/389848

Inventors:

Roy E. Speck - Indianapolis IN

Assignee:

Analytical Control Systems, Inc. - Fishers IN

International Classification:

A61K 3324
A61K 3514

US Classification:

424617

Abstract:

Novel assays and reagents for determining coagulative properties of blood or plasma are disclosed, as are agents and methods for stemming bleeding. Novel ellagic acid-based activators consist essentially of aqueous solutions of ellagic acid, phenol and suitable metal ions and give defined values for a novel platelet assay also disclosed. Inventive coagulation reagents including propyl gallate or tannin are also disclosed, as are aPTT reagents having sensitivity to heparin and Factor deficiencies far superior to prior aPTT reagents. Disclosed heparin-sensitive reagents include dextran sulfate. Also disclosed is applicant's discovery that reagents including hydroxy-substituted compounds and metal ions, heretofore known to activate Hagemann Factor, also cause platelets to release Platelet Factor 3, and a series of platelet-sensitive tests found to be enabled by this discovery. These platelet-sensitive tests include assays for platelet activity, systemic lupus, platelet reserve, which can signify type II lipoprotein defects, and for Platelet Factor 4. Disclosed methods and materials for stemming bleeding center around applicant's discovery that bleeding from bleeding sites can be stopped up to six time faster by applying to the site a hemostatic agent including effective amounts of hydroxy-substituted aromatic compound and metal ion.

US Patent:

54515092, Sep 19, 1995

Filed:

Nov 29, 1993

Appl. No.:

8/158538

Inventors:

Roy E. Speck - Indianapolis IN

Assignee:

Analytical Control Systems, Inc. - Fishers IN

International Classification:

C12Q 156
G01N 3386

US Classification:

435 13

Abstract:

Novel assays and reagents for determining coagulative properties of blood or plasma are disclosed, as are agents and methods for stemming bleeding. Novel ellagic acid-based activators consist essentially of aqueous solutions of ellagic acid, phenol and suitable metal ions and give defined values for a novel platelet assay also disclosed. Inventive coagulation reagents including propyl gallate or tannin are also disclosed, as are aPTT reagents having sensitivity to heparin and Factor deficiencies far superior to prior aPTT reagents. Disclosed heparin-sensitive reagents include dextran sulfate. Also disclosed is applicant's discovery that reagents including hydroxy-substituted compounds and metal ions, heretofore known to activate Hagemann Factor, also cause platelets to release Platelet Factor 3, and a series of platelet-sensitive tests found to be enabled by this discovery. These platelet-sensitive tests include assays for platelet activity, systemic lupus, platelet reserve, which can signify type II lipoprotein defects, and for Platelet Factor 4. Disclosed methods and materials for stemming bleeding center around applicant's discovery that bleeding from bleeding sites can be stopped up to six times faster by applying to the site a hemostatic agent including effective amounts of hydroxy-substituted aromatic compound and metal ion.